Fig. 4: Identification of lncRNA NORAD in EVs in M2 macrophages. | npj Precision Oncology

Fig. 4: Identification of lncRNA NORAD in EVs in M2 macrophages.

From: M2 macrophage-derived lncRNA NORAD in EVs promotes NSCLC progression via miR-520g-3p/SMIM22/GALE axis

Fig. 4

A EVs derived from THP-1 cells as identified by TEM. B EVs derived from THP-1 cells as identified by NTA. C The expression of lncRNA NORAD in M0, M1, and M2 macrophage-derived EVs. D The protein level of exosome markers (TSG101, Alix, HSP70, and CD81) in M0, M1, and M2 macrophage-derived EVs or MDM-derived EVs. E–H The mRNA level of M1 macrophage markers (CD86, TLR2, and NOS2) or M2 macrophage markers (ARG1, CD163, and CD206) in THP-1 cell-derived EVs or MDM cells. I The expression of miR-520g-3p in NSCLC cells after treatment with different macrophage-derived EVs. J Immunofluorescence of PKH67 in NSCLC cells. K, L The expression of lncRNA NORAD in M2 macrophages or M2 macrophage-derived EVs. M The expression of miR-520g-3p in NSCLC cells after treatment with different groups of M2 macrophage-derived EVs. N, O The expression of lncRNA NORAD in NSCLC cells after treatment with M2 macrophage-derived EVs and inhibitors. Error bars represent the means ± SEM of three independent experiments. EVs: extracellular vesicles; MDM: monocyte-derived macrophage; OE: over-expression; NC: negative control. ∗∗p < 0.01.n,s., not significant.

Back to article page